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2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a
mechanism independent of DNA hypomethylation
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Summary The chemotherapeutic agents 2'-deoxy-5-azacytidine (DAC) and cisplatin (cDDP) have been shown
in vitro to be synergystic in their cytotoxicity toward human tumour cells. We have investigated possible
molecular mechanisms underlying this synergy using the plasmid pSVE3 in vitro and after transfection into
CMT3 cells. Increased binding of cDDP to DAC-substituted DNA generated in vivo was confirmed by
flameless atomic absorption spectrophotometry (FAAS). The plasmid used in these experiments was
unmethylated suggesting that DAC was effective in enhancing cDDP binding to DNA without acting as a
hypomethylating agent, but by directly changing the topology of DNA. The role of DNA methylation in
cDDP binding was studied using methylated and unmethylated plasmid incubated in vitro with cDDP.
Restriction analyses and FAAS measurement of bound platinum indicated that methylated DNA bound more
cDDP than unmethylated DNA. In addition, in vivo studies confirmed the in vitro observations since
replication of methylated plasmid was inhibited to a greater extent than unmethylated plasmid.
Many factors are considered when selecting the drugs to be
included in a regimen of combination chemotherapy. Fre-
quently, agents are chosen based on toxicity profiles and
demonstrated efficacy in clinical trials. Occasionally, in vitro
cytotoxicity assays will suggest a synergistic interaction (i.e.
the effect of the two drugs together is greater than the
predicted additive effect), and this information can be used in
designing treatment protocols. Previous studies from our
laboratory, using human tumour cell lines, showed that
synergistic cytotoxicity can be demonstrated between 2'-
deoxy-5-azacytidine (DAC) and cis-dichlorodiaminoplatinum
(cDDP) (Frost et al., 1990). The mechanism for synergy
between cDDP and DAC remains to be elucidated.
Theoretically, synergy between two drugs can occur at
several cellular levels. One drug may increase cellular uptake
of a second drug, or inhibit its removal from the cell.
Metabolism of the second drug could be altered in a way
that the drug persists in an active form for a longer time. For
compounds that act at the level of DNA, incorporation or
binding may be enhanced. The synergistic interaction
between cDDP and DAC may likely take place at the DNA
level, as this is where both drugs are known to exert their
effects. cDDP binds directly to DNA, producing both intra-
strand and interstrand crosslinks (Bird, 1978; Caradona et
al., 1982; Pinto & Lippard, 1985). The intrastrand crosslink-
ing is most frequent at N7 of adjacent guanosines. DAC is
an analog of deoxycytidine, substituting a nitrogen for car-
bon 5 of the pyrimidine ring. DAC is incorporated into
DNA (Vesely & Cihak, 1977) and functions as a DNA
methyltransferase inhibitor (Creusot et al., 1982). The result-
ing DNA hypomethylation has been shown to be associated
with changes in gene expression and cell differentiation
(Jones & Taylor, 1980; Razin & Riggs, 1980).
We have investigated the molecular mechanisms underlying
the synergy between DAC and cDDP. Using the plasmid
pSVE3 as an indicator of cDDP binding to DNA, we are
able to show that these two drugs interact at the DNA level.
The effect of DAC is to increase cDDP binding to DNA as
shown by flameless atomic absorption spectrophotometry
(FAAS). Using methylated and unmethylated pSVE3 DNA,
we show that hypomethylation does not reproduce the cDDP
binding effects of DAC, suggesting that DAC may induce
other alterations in DNA, such as topologic changes, that
could lead to enhancement of cDDP binding.
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Materials and methods
Plasmidpreparation
The plasmid pSVE3 (Hartman et al., 1982), was isolated
from E. coli DH5 cells (Hanahan, 1983) using the alkaline
extraction method followed by CsCl density centrifugation
and extensive dialysis as previously described (Sambrook et
al., 1989).
Cells and culture conditions
CMT3 cells (Gerard & Gluzman, 1985) were maintained in
Dulbecco's Modified Eagle Medium (DMEM) (Gibco,
Grand Island, NY) supplemented with L-glutamine
(292 ygml-'), penicillin (500 U ml-1), streptomycin sulphate
(100fig ml-'), 10% fetal bovine serum (Hazleton, Lenexa,
KS) at 37°C in a 10% CO2 humidified incubator.
Determination ofDAC incorporation into DNA
CMT3 cells were plated in two 35 mm diameter wells at a
density of 250,000 cells per well and incubated overnight at
37°C. On the following day, DAC and cDDP were prepared
and added to the cells. Thirty-two microliters of [3H]-DAC,
specific activity 8 Ci mmolh', lmCi ml-', (Moravek
Biochemicals Inc., Brea, CA) were lyophilised and
resuspended in 4 ml of media to a final concentration of
1 liM. The plated CMT3 cells were washed with PBS and
2 ml of the [3H]-DAC-containing media were added to each
of the two wells. cDDP (obtained through Dr Ruth Davis of
the NIH) was prepared in PBS at a concentration of
1.67 mM, and added to one of the wells to a final concentra-
tion of 5tM. Ten microliters of media were removed from
each well to 2.5 cm diameter 3MM filter paper discs (What-
man Ltd., Maidstone, Eng.). These discs were designated set
A. Cells were incubated with the drugs overnight. On the
next day, the media was removed and cells washed with PBS.
Then, 400jil of a solution of 100ftl proteinase K (1 mgml-')
in 2 ml of a buffer containing 40mM Tris. HCI (pH 7.5)
0.5% sodium dodecyl sulfate, 10 mM EDTA was added to
each well. After gentle mixing the cell lysate was removed to
1.5 ml centrifuge tubes and incubated at 37°C for one hour.
The suspension was then extracted twice with one volume of
phenol:chloroform (1:1), precipitated with 0.3M Na acetate
and three volumes of ethanol, and resuspended in 200fil
H20. Two 50 IA aliquots were added to separate filter paper
discs (sets B and C). To a third 50 gLl aliquot, 1OM NaOH
was added to a final concentration of 0.5 M. After a 30 min
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incubation at 37°C, the NaOH treated samples were applied
to filter paper discs (set D). The purpose of the incubation in
alkali was to degrade RNA to quantitate incorporated counts
on DNA only. We have also used alternatively RNAse A
treatment in other experiments obtaining similar results. Disc
sets C and D were ashed gently for 10 min in a 10% solution
of trichloroacetic acid, in an ice bath. The discs were sub-
sequently rinsed twice with 5% trichloroacetic acid, followed
by two rinses with 70% ethanol. After addition of scintil-
lation fluid, all discs (sets A-D) were counted on a Beckman
LS 3881 scintillation counter.
Transfection ofCMT3 cells and treatment with cDDP and
DAC
CMT3 cells were trypsinised and plated at 2 x 106 cells per
9 cm2 plate one day prior to the DNA transfection. The cells
were transfected with 20;gg of pSVE3 per plate, using the
calcium phosphate precipitation method as previously de-
scribed (Chernajovsky, 1989). On the following day, the cells
were osmotically shocked for 4 min with 1 ml DMEM con-
taining 10% glycerol, and washed with serum-free media.
Five ml of fresh media were then added. DAC (Phar-
machemie B.V., Haarlem, Netherlands) was prepared fresh in
water as a stock solution of 2.1 mM. cDDP was prepared
immediately prior to use as a stock solution of 3.3 mM in a
buffer of 3 mM NaCl, 1 mM NaH2PO4, pH 7.5 (Ushay et al.,
1981). The drugs were added directly to the cell culture
media to the final concentrations stated in the figure legends.
If both drugs were used, DAC was added first followed 2 h
later by cDDP. All drug treatments were performed at 37°C
for 48 h.
Extraction, purification, quantitation and labelling ofepisomal
DNA from CMT3 cells
After transfection and incubation with the drug(s), episomal
DNA was extracted from CMT3 cells using a modification of
the method described by Hirt (Hirt, 1967). Briefly, one ml of
Hirt buffer (0.6% SDS, 0.01 M EDTA, 0.01 M Tris.HCl pH
7.9) was added to each 9 cm2 plate and the cell lysate was
collected at 4°C. Two hundred-fifty microliters of 5 M NaCl
were added to each sample and after gentle mixing, the
samples were stored overnight at 4C. Samples were then
centrifuged at 12,000 RPM at 4°C for 30 min in a SS34
Sorvall rotor to remove genomic DNA and cellular debris.
The supernatant was extracted twice with water saturated
phenol containing 0.1% (w/v) hydroxyquinoline. The ex-
tracted nucleic acids were then precipitated with the addition
of 2.5 volumes of 100% ethanol and incubated overnight at
- 20°C. After centrifugation, the pellet was resuspended in
80 iAI water and treated for 30 min at 37°C with 10 jil RNAse
A (1Omg ml-) in a reaction volume of 100yIA containing
20mM Tris.HCl pH 7.5, 50mM NaCl, and 10mM MgCl2.
Then lOtLI proteinase K (1 mgml-'), 150lI of 40mM
Tris.HCl pH 7.5, 0.5% sodium dodecyl sulphate and 10 mM
EDTA were then added and the samples were incubated for
30 more minutes at 37°C. The reaction was stopped by a 1:1
extraction with water-saturated phenol. The nucleic acids
were then precipitated in 2 M NH4-acetate and 2.5 volumes of
absolute ethanol, and resuspended in 100IlI water. DNA
concentration was determined by measuring optical density
at 260 nm. Equal amounts of DNA from each sample were
digested with restriction enzymes and the DNA fragments
were separated by agarose gel electrophoresis.
In hybridisation experiments, DNA was deaminated in situ
with 0.25 M hydrochloric acid for 30 min and blotted from
the gel to Nytran nylon membranes (Schleicher and Schiill,
Keene, NH) as decribed by Southern (Southern, 1975) using
alkaline conditions (Chomczynski & Qasba, 1984). Hind III
digested pSVE3 DNA was labeled with a[32P] dCTP by ran-
dom priming (Feinberg & Vogelstein, 1983). Nytran filters
were hybridised and washed as recommended by the supplier.
Filters were exposed to autoradiography at - 70°C with
Kodak XAR-5 film, using intensifier screens.
Binding ofcDDP topSVE3 in vitro
All in vitro incubations of cDDP with plasmid DNA were
performed overnight at 37°C. A stock solution of 3.3 mM
cDDP was prepared in a buffer containing 3 mM NaCl, 1 mM
NaH2PO4, pH 7.5, as described (Ushay et al., 1981). The
reaction mixture was in 18 tlI containing 1 "l DNA and
26.5 tLM cDDP. At the end of the reaction the sample was
diluted in water to a final volume of 100ftl. Unbound cDDP
and buffer were removed by centrifugation through a G-50
fine Sephadex spin column equilibrated in 20 mM Hepes.
KOH pH 7.9, Binding of cDDP to plasmid DNA was deter-
mined by restriction analysis of 0.5 fig DNA or by flameless
atomic absorption spectrometry (see below).
Determination ofplatinum bound to DNA
Platinum bound to DNA was determined using a Varian
model 1475 atomic absorption spectrophotometer equipped
with a Varian GTA-95 graphite tube atomiser and
automated sampler. This assay for platinum content has been
described previously (Newman et al., 1986).
DNA methylation and restriction analysis
pSVE3 DNA was digested with Bam HI, Hpa II, Msp I or
Hha I restriction enzymes as recommended by the suppliers (Boeringher Manheim, Indianapolis, IN). Site specific DNA
methylation with Hpa II or Hha I methylase was also per- formed in accordance with the recommendation of the supp- lier (New England Bio-Labs, Beverley, MA). The completion
of the methylation reaction was tested by inhibition ofdiges-
tion with the appropriate restriction enzyme. DNA restric-
tion fragments were separated on 1.2 or 1.5% agarose gels in
45 mM Tris.borate, 1.25 mM EDTA and 0.5 fgml-' ethidium
bromide at 100 volts for one to two hours.
Results
DAC uptake andincorporation
In order to demonstrate that DAC is incorporated into the
DNA of CMT3 cells, 1 ,LM [3H]-DAC in media was added to
semiconfluent CMT3 cells. To determine if cDDP altered
DAC uptake or incorporation, the cells in one of the wells
were simultaneously treated with 5tIM cDDP. After an over-
night incubation, the cells were lysed and DNA extracted.
The [3H]-DAC content in the media, total cellular lysate,
total nucleic acids, and DNA was determined by scintillation
counting. Results are shown in Table 1. Approximately
0.3-0.4% of the counts added to the media are eventually
found in DNA. Of interest, the counts in DNA represent
only 25-35% of the counts in total nucleic acids, suggesting
that there may also be incorporation into RNA. In the
presence of cDDP, there is decreased cellular uptake of
DAC. However, the levels of DAC incorporated into DNA
were not affected by the presence of cDDP, but the incor-
poration into RNA was reduced by almost 50%.
Table I Incorporation of[3H]-DAC into DNA ofCMT3 cells in the
presence or absence of cDDP
CPM
DAC DAC + cDDP
Set A-Media 3,781,900 3,978,400
Set B-Total intracellular 86,408 51,024
Set C-Total nucleic acids 65,924 35,486
Set D-DNA 15,764 12,332
For Set A, counts from 10 yI media were multiplied by 200 to
calculate total counts in 2 ml media. For Sets B, C, and D, counts
from 50 sl aliquots were multiplied by four to calculate total counts in 200IlI samples. Numbers represent the average of two experiments
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The effect ofDAC substitution ofcDDP binding to DNA
cDDP has been shown to inhibit replication of viral SV40
DNA (Cicarelli et al., 1985). If DAC interacts with cDDP at
the DNA level, it would be anticipated that DAC-substituted
viral SV40 DNA would bind more cDDP. To study this
potential interaction we used the 5.3 Kb eukaryotic vector
pSVE3 (Hartman et al., 1982), which contains the SV40
origin of replication and early genes in a 3.3 Kb viral DNA
fragment (Figure 1). The remaining 2.0 Kb of plasmid DNA
is derived from pBR322 and contains numerous GC-rich
regions, included in Hpa II and Hha I restriction sites.
CMT3 cells, a simian cell line derived from CV-1 cells
(Gerard & Gluzman, 1985), were used for transfection
studies. CMT3 cells constitutively produce a low level of T
antigen so that when pSVE3 is transfected into this cell line,
it replicates and is maintained episomally (Gerard & Gluz-
man, 1985).
To demonstrate that the effect on plasmid replication was
actually a function of increased cDDP binding to DAC-
treated DNA, we transfected CMT3 cells with pSVE3, and
treated half of the plates with 1 JAM DAC. DAC-substituted
and unsubstituted episomal DNA was isolated and incubated
in vitro with 26.5 JAM cDDP overnight. cDDP binding was
quantitated by FAAS. The increased binding of cDDP to
DAC-treated DNA is shown in Table II.
The plasmid DNA used in these experiments was
unmethylated. This minimised the possibility of DAC pro-
ducing its effects through DNA hypomethylation. However,
since hypomethylation is a well established DAC-induced
alteration in DNA, we proceeded to investigate the role of
methylation and hypomethylation on the binding ofcDDP to
DNA.
DNA methylation and cDDP binding in vitro
When cDDP is bound to DNA at a restriction site, digestion
by the specific endonuclease is inhibited (Ushay et al., 1981).
Taq I
Bgl I
Table II In vitro cDDP binding to DAC-substituted or non-
substituted DNA
Ratio cDDP/DNA (ng ug-')
DAC-substituted non-substituted
exp. 1 78.67 56.03
exp. 2 85.00 69.23
Episomal DNA (15rAg) isolated from DAC-treated (I jiM) or
untreated CMT3 cells was incubated in vitro with 26.5JAM cDDP
Bound platinum was measured by FAAS (see Methods).
Lack of appropriate restriction can therefore, be used to
assay for cDDP binding. Methylated and unmethylated
restriction sites, exposed to cDDP, can be compared by their
ability to be cleaved. The pBR322 fragment of pSVE3 con-
tains nine Hpa II sites (CCGG) and eleven Hha I sites
(GCGC). The cytosines in these sites were methylated with
site specific Hpa II or Hha I methylase. Methylated and
unmethylated plasmid digested with Bam HI was then
incubated overnight with 26.5jiM cDDP. The extent of
cDDP binding was evaluated by assessing the degree of
digestion with the appropriate restriction enzyme. A half
microgram of cDDP-treated methylated plasmid, cDDP-
treated unmethylated plasmid, and untreated methylated and
unmethylated control plasmid, were restricted with Hpa II,
Msp I, or Hha I. Hpa II and Hha I normally cut only
unmethylated DNA, whereas Msp I, and isoschizomer of
Hpa II, will cut both methylated and unmethylated Hpa II
sites. Using these enzymes, the restriction products were
analysed by agarose gel electrophoresis. The results of these
studies are shown in Figure 2. Lanes 1-3 show the normal
restriction pattern of unmethylated pSVE3 for Hpa II, Msp
I, and Hha I. As expected, Hpa II and Msp I show identical
patterns. Methylation of Hpa II sites completely inhibits
digestion by Hpa II (lane 4) but has no effect on Msp I (lane


















Figure 1 Restriction map and distribution of Hpa II and Hha I restriction sites in pSVE3. pBR322 sequences appear as a dotted
bar, SV40 sequences in black. The arrows represent the direction of transcription of the E. coli ampicillinase (A) gene or the SV40
early T antigens (T).212 J.A. ELLERHORST et al.
Figure 2 In vitro binding of cDDP to pSVE3 DNA inhibits restriction enzyme cutting and this inhibition is increased in Hpa II
methylated DNA. Linearised pSVE3 DNA, unmethylated (lanes 1-3 and 7-9) or methylated at Hpa II sites (lanes 4-6 and
10-12), was treated with restriction endonucleases after incubation with cDDP (lanes 7-12) or no drug exposure (lanes 1-6).
Restriction enzymes include Hpa II (lanes 1, 4, 7, 10); Msp 1 (lanes 2, 5, 8, 11); and Hha 1 (lanes 3, 6, 9, 12). Digestion of
cDDP-treated methylated DNA is more inhibited than that of cDDP-treated non-methylated DNA. Lane M contains a molecular
weight marker (A phage DNA digested with Hind III).
cDDP, all three enzymes show a partial restriction pattern
(obvious also from the presence of uncut residual 2 kb Bam
HI pBR322 DNA fragment) (lanes 7-9) indicating that
bound cDDP is interfering with restriction. Hpa II
methylated pSVE3 treated with cDDP is uncut by Hpa II as
expected (lane 10). Surprisingly, Msp I is also completely
inhibited in its ability to restrict cDDP-treated methylated
DNA, in contrast to partial inhibition with cDDP-treated
unmethylated DNA (compare lanes 11 and 8). It is also
shown in Figure 2 that when the DNA is methylated at Hpa
II sites and treated with cDDP, the increased inhibition of
restriction is found at the Hha I sites (compare lanes 9 and
12). The converse is also true. Hha I methylated DNA
treated with cDDP is more resistant to digestion by both
Hha I and Hpa II, when compared to unmethylated DNA
(Figure 3). These restriction studies suggest that (1)
unmethylated DNA appears to bind less cDDP than
methylated DNA, and (2) the effect of methylation on in-
creased cDDP binding is found beyond the immediate
environment of the methylated restriction site.
DNA methylation and cDDP binding in vivo
In another set of experiments, we transfected CMT3 cells
with Hpa II methylated and unmethylated pSVE3. Cells were
then treated with cDDP at a concentration of 0.0, 0.5, 1.0,
5.0, 25.0, or 53tLM for 48 h. Non-chromosomal (mitochond-
rial plus episomal) DNA was subsequently extracted. One
microgram of DNA from each plate was digested with Msp I
and the fragements separated by agarose gel electrophoresis.
The DNA was transferred to a nylon membrane and probed
with pSVE3. Figure 4 shows the resulting autoradiograph.
Episomal DNA recovered from cells transfected with
unmethylated DNA is in lanes 1-6; lanes 7-12 contain
DNA from cells transfected with methylated DNA. At con-
centrations of cDDP at or above I gLM, the recovery of
methylated pSVE3 is clearly less than that of unmethylated
pSVE3; indicating that replication ofmethylated plasmid was
inhibited to a greater extent, again suggesting that
methylated DNA binds more cDDP than unmethylated
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Figure 3 In vitro binding of cDDP to pSVE3 DNA inhibits restriction enzyme cutting and this inhibition is increased in Hha I
methylated DNA at both Hha I and Hpa II sites. Linearised pSVE3 DNA, unmethylated (lanes 1-3 and 7-9) or methylated at
Hha I sites (lanes 4-6 and 10-12), was treated with restriction endonucleases after incubation with cDDP (lanes 7-12) or no drug
exposure (lanes 1-6). Restriction enzymes include Hpa II (lanes 1, 4, 7, 10); Msp I (lanes 2, 5, 8, 11); and Hha I (lanes 3, 6, 9, 12).
Inhibition of restriction is seen in cDDP-treated methylated DNA at sites distant from the methylation site. Lane M contains a
molecular weight marker (A phage DNA digested with Hind III).
Finally, we incubated 3 jig of either Hpa II methylated or
unmethylated pSVE3 overnight with 26.5ylM CDDP. After
removing unbound cDDP and buffer, samples were analyzed
for bound platinum by FAAS. Table III shows the increase
in platinum bound to methylated DNA compared to
unmethylated DNA.
Discussion
We have attempted to elucidate the mechanism underlying
the synergistic cytotoxocity between DAC and cDDP. We
first demonstrated that labeled DAC is taken up by CMT3
cells and incorporated into DNA. Surprisingly, we also
detected incorporation of DAC into RNA. DAC has been
shown to be uniquely incorporated into DNA in human
colon carcinoma cells (Glazer & Knode, 1984). However,
different cell types are capable to metabolise DAC in dif-
ferent ways. For example the block in colony forming
activity, caused by DAC, can be relieved either with cytidine
or deoxycytidine in HeLa cells (Snyder & Lachmann, 1989)
but only with deoxycytidine in B16 melanoma cells (Cort-
vrindt et al., 1987) and human leukaemic progenitor cells
(Bhalla et al., 1987). In addition, the activity of the enzyme
cytidine deaminase, which converts cytidine into uridine, was
shown to be increased in HL-60 cells after treatment with
DAC (Momparler & Laliberte, 1990). These studies suggest
that DAC can be shunted into the RNA pool as we have
found.
We showed that in the presence of cDDP, there is de-
creased DAC uptake by CMT3 cells, ruling out the possi-
bility of synergy at the level of drug entry into the cell;
however, this result suggests that cDDP may partially affect
cellular transport of nucleosides by crosslinking proteins at
the cell surface. The fact that addition of cDDP decreased
the incorporation of DAC into RNA may reflect a decrease
in transcription caused by cDDP or an increase in RNA
degradation.
It seems unlikely that DAC could increase incorporation
ofcDDP into DNA. It was shown that DAC upregulates the
expression of metalothionein (Waalkes et al., 1988) which
was also reported as the responsible for the resistance of cells
to cDDP, melphalan and chlorambucil (Kelley et al., 1988).
Thus, only a decrease in the effectivity of cDDP could have214 J.A. ELLERHORST et al.
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Figure 4 Increased sensitivity of Hpa II methylated pSVE3 DNA to cDDP mediated inhibition of DNA replication. CMT3 cells
were transfected with nonmethylated (slots 1-6) or Hpa II methylated DNA (Slots 7-12). The cells were untreated (Slots 1, 7) or
treated with cDDP 0.5 LM (Slots 2, 8); 1 gM (slots 3, 9); 5,m (slots 4, 10); 25 LM (slots 5, 11) or 53 iM (Slots 6, 12).
Non-chromosomal DNA was extracted and restricted with Msp I. After electrophoresis, the nucleic acids were transferred to a
nylon filter and probed with 32P-labelled pSVE3. Hybridisation to the 3.3 kb SV40 DNA fragment is shown.
Table III In vitro cDDP binding methylated and non-
methylated DNA
Ratio cDDP/DNA (ng ltg ')
methylated non-methylated
exp. 1 46.51 34.54
exp. 2 53.57 32.44
Hpa II methylated and non-methylated pSVE3 DNA (3fg) was
incubated in vitro with 26.5tM cDDP. Bound platinum was
measured by FAAS (see Methods).
been expected.
We also showed that in vivo DAC substituted DNA bound
more cDDP than unsubstituted DNA. This result was
confirmed by direct measurements of bound platinum by
FAAS, after incubating cDDP with DAC-substituted and
unsubstituted DNA. These results suggest that the interaction
between the two drugs takes place at the DNA level, the role
of DAC being to increase the amount of bound cDDP. In
these experiments, inhibition of DNA synthesis is the
observed outcome of cDDP binding; however, one could
predict that gene transcription might also be affected.
We attempted to clarify the role of DAC is this enhance-
ment of cDDP binding. DAC is well know for its role in
DNA hypomethylation. During DNA replication, DAC is
incorporated as a cytosine analog into the newly synthesised
strand. The parent strand remains methylated; however, in
the presence of DAC, the action of methyltransferase is
inhibited and the daughter strand is therefore unmethylated
(Cruesot et al., 1982). Because methylation of a daughter
strand requires prior methylation of the parent strand, sub-
sequent round of DNA synthesis after DAC substitution
result in generally hypomethylated DNA (Bird, 1978). It
would seem possible, then, that DAC-induced hypomethylat-
ion might reveal additional cDDP binding sites, particularly
in GC-rich regions such as occur frequently in eukaryotic
promotors and other regulatory sites. In favour of such
suggestion is the observation that increased protein binding
to DNA was found at hemymethylated sites after DAC
treatment (Michalowsky & Jones, 1987); since cDDP cross-
links both proteins and DNA (Ciccarelli et al., 1985) such
sites could provide for an excellent substrate for cDDP bin-
ding. However, against this explanation is the fact that we
were able to demonstrate synergy between DAC and cDDP
in a system where further hypomethylation could not occur,
i.e. by using a plasmid substrate that was already
unmethylated. Yet, the possibility that DAC itself increases
protein binding to DNA can not be ruled out.
The lack ofenhancement of cDDP binding to hypomethyl-
ated DNA was subsequently shown by FAAS, restriction
analysis, and in vivo DNA replication studies comparing
cDDP-treated methylated and unmethylated plasmid DNA.
In fact, methylated DNA is found in all three experimental
systems to bind more cDDP than unmethylated DNA. This
has led us to conclude that the role of DAC in enhancing
cDDP binding to DNA is independent of its role as a
hypomethylating agent. This is consistent with the results of
Frost et al., who were unable to correlate the degree of
DAC/cDDP synergy in cytotoxicity assays with the extent of
DNA hypomethylation (Abbruzzesse & Frost, 1992; Frost et
al., 1990).
The enhancement of cDDP binding to methylated DNA
was surprising. Methylation of cytosines is thought to play a
role in regulation of gene function (Jones & Taylor, 1980)
and transcriptionally active mammalian genomic DNA is
frequently hypomethylated (Sanford et al., 1985). Methyl-
ation of cytosines in GC-rich sequences in promoter regions
may inhibit binding of RNA polymerase or other regulatory
proteins, as the methyl group extends into the major groove
(Razin & Riggs, 1980). The role of the methyl group may
simply be to produce steric hindrance. Alternatively,
topologic changes may be involved. Stretches of alternating
purines and pyrimidines are known to adopt the unusual
left-handed Z DNA conformation (Wang et al., 1982) and
this topologic form is stabilised by methylation of cytosines
(Behe & Felsenfeld, 1981). Methylation of a critical promotor
region may produce or stabilise a DNA conformation that is
no longer recognised by the transcriptional machinery.
In a similar manner, the conformation adopted by
methylated DNA may actually make it more accessible to
cDDP. This would predict that cDDP binding should be
enhanced not only at the precise methylation site, but also
for a distance upstream and downstream. The restriction
studies described in Figures 2 and 3 show exactly this effect.
In Figure 2 it is apparent that methylation of Hpa II sites
has resulted in enhanced cDDP binding not only to Hpa II
but also Hha I sites, as evidenced by incomplete restriction
with both enzymes. Conversely, methylation of Hha I sites
and treatment with cDDP limits restriction at Hpa II sites
(Figure 3). We would propose, then, that certain conformat-
ions of DNA are more amenable to cDDP binding, and that
one of these conformations is produced when short stretches
of repetitive GC sequences are methylated.
In view of the above findings with methylated and
unmethylated DNA, it is interesting to speculate about possi-
ble mechanisms for the enhancement of cDDP binding to
DAC-substituted DNA. It appears that hypomethylation is
not necessary for DAC to produce this effect. An alternative
suggestion is that DAC incorporation into DNA might
induce topologic changes that allow for an increase in cDDP
binding, similar to the observation with methylated DNA.
Unfortunately, DAC substituted DNA has not been analysed
by X-ray crystallography, and therefore direct evidence for
DAC-induced DNA conformational changes is lacking.
However, some indirect evidence does exist. Jones and Taylor
(Jones & Taylor, 1980) have shown than an approximate 5%
substitution of 5-azacytidine for cytidine resulted in 80-85%
inhibition of cytidine methylation. This suggests that the
incorporated azanucleotide produces an effect distant from
its immediate surroundings, similar to that which we have
seen in our restriction studies using cDDP-treated methylated
DNA. Furthermore, DAC-substituted genomic DNA con-SYNERGY OF 2'-DEOXY-5-AZACYTIDINE AND cDDP 215
tains fragile sites (Djalali et al., 1990), and is more labile to
single stand cleavage in alkali (D'Incalci et al., 1985).
Marked alterations in the chromosome structure and conden-
sation patterns of DNA from GH12C, rat pituitary cells
treated with 5-azacytidine have been reported by Parrow et
al., (Parrow et al., 1989). Additionally, the free azanucleotide
is able to attain different tautomeric forms (Saenger, 1984).
Future studies might be detected towards addressing the
interesting possibility that DNA topologic alterations might
occur secondary to DAC incorporation. Insight could be
gained into the role of this compound as a hypomethylation
agent, a differentiation agent, and a cancer chemotherapeutic
drug.
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